Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment by Black, S, Wilcock, G, Zavitz, K, Hendrix, S, Swabb, E

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. by Wilcock, G, Black, SE, Hendrix, S, Zavitz, K, Swabb, E, Laughlin, M

Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment by Wilcock, G, Black, SE, Hendrix, S, Zavitz, K, Laughlin, M, Swabb, E

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. by Green, R, Schneider, L, Amato, D, Beelen, A, Wilcock, G, Swabb, E, Zavitz, K

Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind tr... by Wilcock, G, Black, S, Haworth, J, Laughlin, M, Hendrix, S, Binger, M, Zavitz, K, Swabb, E, Hobden, A

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study by Black, S, Wilcock, G, Haworth, J, Hendrix, S, Zavitz, K, Christensen, D, Binger, M, Bass, S, Laughlin, M, Swabb, E